The Glo-BNHL trial is the largest platform trial in paediatric and adolescent relapsed and refractory B-cell malignancies globally.
It has been developed in collaboration with a number of international partners, including Innovative Therapies for Children with Cancer (ITCC) and European Intergroup for Childhood NHL (EICNHL) in Europe; Children's Oncology Group (COG) and C17 in North America; and the Australia and New Zealand Children’s Haematology and Oncology Group (ANZCHOG).
The platform is aiming to test a wide range of therapies over the lifetime of the trial with the aim of finding better treatments and, ultimately, a cure for this rare paediatric cancer.
Find out more about the trial and how to get involved
Find out more about the trial design and access our publications
Access information for hospitals and download current trial documentation
Find out further information on current industry partners, trial design and contractual arrangements
Also in 'Glo-BNHL'